Novel Diabetes Care

CME Activities

• Diabetes Dialogue Part 2: Who Are Candidates for GLP-1 Receptor Agonist Therapy in Primary Care?
  Medscape Education, March 2023
  Who should be taking a glucagon-like peptide-1 (GLP-1) receptor agonist (RA)? Join Drs Bain and Lin to find out.
  0.25 CME

  0.25 ABIM MOC
• Diabetes Dialogue Part 1: Pursuing Holistic Treatment Concepts With GLP-1 Receptor Agonists in Primary Care
  Medscape Education, March 2023
  Do you know when and how to start a glucagon-like peptide-1 (GLP-1) receptor agonist (RA)? Join Professors Khunti and Vilsbøll to find out.
  0.25 CME

  0.25 ABIM MOC
• The Revised Role of GLP-1 Receptor Agonists in Diabetes Care – Above and Beyond Glycemic Control?
  Medscape Education, March 2023
  How do you choose optimal treatment for patients with type 2 diabetes (T2D)? Drs Seidu, Sattar, and Gorgojo-Martínez discuss.
  0.50 CME
• Classico esempio: uso appropriato di un agonista del recettore del peptide-1 glucagone-simile nelle cure primarie di pazienti con diabete non controllato
  Medscape Education, February 2023
  Il consenso dell’American Diabetes Association/European Society for the Study of Diabetes (ADA/EASD) sul diabete di tipo 2 (DT2) è stato recentemente aggiornato. State applicando le ultime raccomandazioni per la cura dei vostri pazienti con rischio cardiorenale?
  1.00 CME
• A Case in Point: The Appropriate Use of a Glucagon-Like Peptide-1 Receptor Agonist in Patients With Uncontrolled Diabetes in Primary Care
  Medscape Education, November 2022
  The American Diabetes Association/European Society for the Study of Diabetes (ADA/EASD) type 2 diabetes (T2D) consensus was recently updated. Are you applying the latest recommendations to the care of your patients with cardiorenal risk?
  1.00 CME
• Comprehensive Care of the Patient With Diabetes at High Cardiovascular Risk: Cardiology First?
  Medscape Education, October 2022
  Did you know that cardiovascular disease (CVD) is the main cause of death among patients with type 2 diabetes (T2D)?
  0.50 CME

  0.50 CE
• Comprehensive Risk Management of the Diabetes Patient in Primary Care
  Medscape Education, September 2022
  Type 2 diabetes (T2D) is a major risk factor for the development of cardiorenal complications. Hear about talking to your patients regarding risk and the need for treatment.
  0.25 CME
• Best Practice Cardiology Care for the Patient With Diabetes and High CV Risk
  Medscape Education, April 2022
  Join Dr Steg as he reviews this case of T2D management in a patient with high cardiovascular (CV) risk.
  0.25 CME
• Vital Facts About Multi-Faceted GLP-1 RAs for the Cardiology Team: Short Questions -- Prompt Replies
  Medscape Education, April 2022
  Join Dr Wysham and Mr Burnett as they discuss both the use of GLP-1 RAs in cardiology and the role of nurses.
  0.25 CME
• Stroke Prevention in Diabetes: A Decree for Collaboration Between Primary and Secondary Care
  Medscape Education, April 2022
  Join Drs Khunti, Molina, and Pratley as they discuss stroke prevention in type 2 diabetes.
  0.50 CME

• The Evolving Role of Digital Health Solutions for Patients With Diabetes on Insulin
  Medscape Education, December 2022
  Missing even a few insulin doses can impair glucose control. Find out how digital tools can help patients better manage insulin administration and control their glucose levels.
  0.25 CME
• Digital Health for Patients With Type 2 Diabetes on Complex Insulin Regimens
  Medscape Education, December 2022
  Did you know that almost one-third of patients have difficulty taking insulin on time? Learn how digital tools can help reduce dosing errors.
  0.25 CME
• Once-Weekly Basal Insulins: What We Know So Far
  Medscape Education, October 2022
  Up to one-third of patients with type 2 diabetes (T2D) are poorly adherent to insulin therapy; how can this be improved?
  0.75 CME
• Novel Once-Weekly Basal Insulins: Expert Interpretation of Latest Clinical Data
  Medscape Education, October 2022
  Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
  0.50 CME